The objectives of this study are: 1. To characterize the time course of herbs/spice action on endothelial function as measured by FMD over 24 h using a challenge meal paradigm. 2. To assess effects of herbs/spices on metabolic indices (ie., glucose, insulin), and inflammatory markers such as cytokines (ie., IL-6, TNF-alpha) and vascular adhesion molecules (ICAM and VCAM).
The proposed study will be conducted in humans according to Good Clinical Practice (GCP) guidelines. All subjects will review and sign an Informed Consent Form approved by the Illinois Institute of Technology's Institutional Review Boards (IRB) prior to screening. This single-center clinical trial is a randomized, blinded, 4-arm, placebo-controlled, within subject cross-over trial, featuring a repeated postprandial sampling paradigm to evaluate the effects of spice/herb intake on endothelial function, inflammation, insulin sensitivity / glucose handling and vascular function in overweight/obese adults after consuming a standardized challenge meal. A planned sample size of 24 will be enrolled into the study. This study will require one initial screening visit and 4 study visits. This study will take approximately 4-5 weeks per subject to complete. The initial screening visit will provide subject with their site-specific, IRB-approved informed consent document prior to the start of any study related procedures. Subject eligibility will be determined through anthropometric measurements, vital signs, fasting blood glucose test (finger prick), and completion of a survey relate to general eating, health, mood and exercise habits. Eligible subjects will follow a limited polyphenolic diet throughout the duration of their participation, although stricter guidelines will be imposed during the 3 days prior to a study visit. Shopping lists and meal plans will be provided to subjects, along with counseling by our study dietitians, to help subjects adhere to the limited polyphenolic diet. The trial will initiate with a 3-day food diary to assess background (pre-study) dietary intake followed by counseling to follow a diet relatively low in (poly)phenolic rich-beverages/foods, which will be maintained for the duration of the experiment. After an initial 7-day run-in period on the limited polyphenolic diet, subjects will be randomized to 1 of 4 treatment sequences. Treatment codes will be maintained by the principal investigator/study physician. All subjects will receive four treatments, once each on 4 different occasions and separated by at least 4 days. Italian Herb mix, Cinnamon, Pumpkin Spice or placebo will be provided with a standardized meal. Each visit will last \~8 hours and subjects will be required to remain at the Clinical Unit for the duration of the visit. Blood samples will be collected at 0 (fasting) and at 0.5 h, 1 h, 2 h, 4 h, 5.5 h, 7 h and 24 h via a catheter placed on the non-dominant arm by a registered nurse. FMD or NIRS will be conducted at the CNRC or the HNRCA, respectively at 0 (fasting) and at 1 h, 2 h, 4 h, 5.5 h, 7 h and 24 h.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Enrollment
28
Italian Herb in active breakfast meal
Cinnamon in active breakfast meal
Pumpkin Spice Mix in active breakfast meal
Clinical Nutrition Research Center
Chicago, Illinois, United States
Changes in postprandial endothelial function among 4 treatments measured in percent flow mediated dilation
Vascular Assessments will be measured with Flow mediated vasodilation (FMD)
Time frame: Baseline to 24 hours
Changes in Plasma Interleukin-1 β (IL-1β) concentration response among 4 treatments.
Inflammatory cytokines (Interleukin-1 β (IL-1β) will be measured using single target ELISA technology (R\&D Systems).
Time frame: Baseline to 24 hours
Changes in Plasma Interleukin-6 (IL-6) concentration response among 4 treatments.
Inflammatory cytokines (Interleukin-6 (IL-6) will be measured using single target ELISA technology (R\&D Systems).
Time frame: Baseline to 24 hours
Changes in Plasma Tumor Necrosis Factor-α (TNF-α) concentration response among 4 treatments.
Inflammatory cytokines (Tumor Necrosis Factor-α (TNF-α) will be measured using single target ELISA technology (R\&D Systems).
Time frame: Baseline to 24 hours
Changes in Plasma intercellular adhesion molecule 1 (ICAM 1) concentration response among 4 treatments.
Inflammatory cytokines (intercellular adhesion molecule 1 (ICAM 1) will be measured using single target ELISA technology (R\&D Systems).
Time frame: Baseline to 24 hours
Changes in Plasma vascular cell adhesion molecule 1 (VCAM 1) concentration response among 4 treatments.
Inflammatory cytokines (vascular cell adhesion molecule 1 (VCAM 1)) will be measured using single target ELISA technology (R\&D Systems).
Time frame: baseline to 24 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Placebo in breakfast meal